Format

Send to

Choose Destination
Int Arch Allergy Immunol. 2019;180(4):274-283. doi: 10.1159/000503065. Epub 2019 Oct 16.

Efficacy of Desloratadine and Levocetirizine in Patients with Cedar Pollen-Induced Allergic Rhinitis: A Randomized, Double-Blind Study.

Author information

1
Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
2
Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan, yokamoto@faculty.chiba-u.jp.
3
Chiba Rosai Hospital, Chiba, Japan, yokamoto@faculty.chiba-u.jp.
4
Chiba Cancer Center, Chiba, Japan.
5
Biostatistics Section, Clinical Research Center, Chiba University Hospital, Chiba, Japan.

Abstract

BACKGROUND:

No comparative study of antihistamines that differ in structural system has been conducted in allergic rhinitis.

OBJECTIVE:

This was a randomized, double-blind, crossover comparative study to verify the efficacy of antihistamines that differ in structural system.

METHODS:

A total of 50 patients with moderate or more severe Japanese cedar pollen-induced allergic rhinitis were randomized to receive either placebo, desloratadine 5 mg (a tricyclic), or levocetirizine 5 mg (a piperazine). One dose of the study drug was orally administered at 9 pm on the day before a pollen exposure test, which was performed for 3 h (9 a.m. to 12 p.m.) to assess symptoms in an environmental challenge chamber (ECC). Nasal and ocular symptoms were compared at an airborne pollen level of 8,000 grains/m3. The primary endpoint was mean total nasal symptom score (TNSS) from 120 to 180 min in the ECC. Subjects with a difference of ≥1 in TNSS between 2 drugs were extracted to the relevant drug-responsive group.

RESULTS:

The difference in TNSS from placebo was -2.42 (p < 0.0001) with levocetirizine and -1.66 (p < 0.01) with desloratadine, showing that both drugs were significantly more effective than placebo in controlling symptoms, but with no statistically significant difference between the 2 drugs. There were 12 subjects in the desloratadine-responsive group and 24 subjects in the levocetirizine-responsive group, with no contributor to response was detected.

CONCLUSION:

Levocetirizine tended to control nasal symptoms more effectively than desloratadine. However, the response to each antihistamine varied among individuals and the predictors to the response are unknown.

CLINICAL TRIAL REGISTRATION NUMBER:

UMIN ID: UMIN000029653.

KEYWORDS:

Allergic rhinitis; Crossover; Desloratadine; Double-blind study; Environmental challenge chamber; Japanese cedar pollen; Levocetirizine; Placebo controlled; Randomized

PMID:
31618733
DOI:
10.1159/000503065
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center